Spectral's EAA(TM) Proven Effective in Veterinary Applications



    TORONTO, June 6 /CNW/ - Spectral Diagnostics Inc. ("Spectral") today
announces the first global presentation of its proprietary Endotoxin Activity
Assay ("EAA(TM)"), for use in veterinary medicine. Mads Kjelgaard-Hansen, DVM,
PhD, Department of Small Animal Clinical Sciences Faculty of Life Sciences
University of Copenhagen will present positive data on the use of EAA(TM) in
the canine population at the American College of Veterinary Internal Medicine,
in Seattle, Washington, June 6 to 9, 2007.
    Spectral continues to expand the use of EAA(TM) in various clinical
areas, including veterinary medicine. The data to be presented supports the
use of EAA(TM) in a non-human patient population. As in humans, Endotoxin has
long been suspected as contributing to illness in many animals. Spectral is
exploring the utility of EAA(TM) in dogs and horses, specifically race horses,
where intestinal translocation of Endotoxin often leads to a fatal outcome,
but can be successfully treated if diagnosed early. The expanded use of
EAA(TM) in veterinary medicine is being studied at several sites in Canada,
the United States and Denmark.
    Endotoxin is the primary mediator stimulating the inflammatory cascade
and often leads to multiple organ failure and severe sepsis. It is also
implicated as the primary cause of complications in end stage renal disease,
burns and organ transplantation. The gastrointestinal tract is a large reserve
for Endotoxin which, if released into the bloodstream, is a potent trigger of
a severe inflammatory response. Spectral's EAA(TM) is the only Endotoxin assay
with regulatory approval from the FDA, Health Canada and EU regulatory
agencies for clinical use. It also receives strong approval ratings from
hospital laboratories which appreciate rapid results and straightforward
methodology.
    "Therapeutic companies are realizing the value of early biomarkers in the
determination of an individual patient's risk and subsequent response to
disease management. The EAA(TM) is well positioned to quickly advance the
medical and veterinary communities towards early recognition and intervention
in endotoxin-related diseases," stated Dr. Paul Walker, President & CEO of
Spectral.

    Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Current products include Spectral's FDA approved rapid diagnostic for sepsis
(EAA(TM)) and its FDA approved rapid diagnostic for West Nile Virus
(RapidWN(TM)), as well as a range of other biological reagents. Spectral's
common shares are listed on The Toronto Stock Exchange under the symbol SDI.

    Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.

    %SEDAR: 00002006E




For further information:

For further information: CONTACT: At: Spectral Diagnostics Inc., Dr.
Paul Walker, Chief Executive Officer, (416) 626-3233

Organization Profile

Spectral Diagnostics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890